The new weight loss drugs, including semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro), work primarily by mimicking a gut hormone called GLP-1 that signals your brain to feel full. At the highest doses in clinical trials, tirzepatide produced an average body weight reduction of nearly 21% over 72 weeks. That’s roughly 50 to 60 pounds for many people, a level of weight loss that previously required surgery.
But “they make you feel full” is only part of the story. These drugs act on multiple systems simultaneously, from your brain’s appetite and reward centers to your stomach’s emptying speed to your pancreas’s insulin output. Here’s what’s actually happening in your body when you take them.
Mimicking a Natural Gut Hormone
When you eat, your intestines release a hormone called GLP-1 (glucagon-like peptide-1). In its natural form, GLP-1 lasts only a few minutes in your bloodstream before enzymes break it down. The new drugs are synthetic versions of GLP-1 that have been chemically modified to survive much longer, circulating for days instead of minutes. That’s why they only need to be injected once a week.
This sustained presence of GLP-1 amplifies the hormone’s normal effects far beyond what a meal would trigger. Your body treats it as a persistent signal that you’ve just eaten, even hours or days after your last meal.
How They Change Your Brain’s Appetite Signals
The weight loss these drugs produce depends on their ability to reach the brain. GLP-1 receptors are scattered across multiple brain regions involved in hunger, fullness, and the motivation to eat. The most critical area appears to be a structure in the brainstem called the nucleus of the solitary tract (NTS), which sits in a region known as the dorsal vagal complex. When researchers knocked out GLP-1 receptors specifically in the NTS, the drugs lost much of their weight loss effect.
But the brainstem is just one piece. GLP-1 receptors also appear in the hypothalamus, which regulates energy balance, and in reward-processing areas like the ventral tegmental area and nucleus accumbens. These are the same regions involved in cravings and the pleasurable feelings associated with food. This is why many people on these drugs report not just feeling less hungry but genuinely losing interest in food, finding that they can walk past a plate of cookies without the usual pull. Some users report reduced cravings for alcohol and nicotine too, likely for the same reason.
At the cellular level, the drugs work through excitatory neurons in the brain rather than inhibitory ones. They activate neurons that produce appetite-suppressing signals while indirectly quieting neurons that drive hunger. The net effect is a recalibration of your brain’s “set point” for how much food feels like enough.
Slowing Your Stomach
These drugs also slow gastric emptying, meaning food stays in your stomach longer after a meal. This creates a physical sensation of fullness that lasts well beyond what you’d normally experience. For shorter-acting versions of GLP-1 drugs, delayed gastric emptying is actually the primary way they control blood sugar spikes after meals.
This effect is a double-edged sword. The prolonged fullness helps with appetite control, but it’s also responsible for the most common side effects: nausea, vomiting, diarrhea, and constipation. These gastrointestinal symptoms are by far the most frequent complaints from people taking GLP-1 drugs, particularly during the early weeks of treatment. In rare cases, some patients have reported that the slowed stomach emptying persisted even after stopping the medication.
Effects on Blood Sugar and Metabolism
These drugs were originally developed for type 2 diabetes, and their metabolic effects extend well beyond appetite. They increase insulin secretion in response to meals, helping your body clear sugar from the bloodstream more efficiently. They also lower levels of glucagon, a hormone that tells your liver to release stored sugar. The combination means lower blood sugar after eating and less sugar being pumped into your blood between meals.
Importantly, the insulin boost is glucose-dependent, meaning the drugs stimulate insulin only when blood sugar is elevated. This makes dangerously low blood sugar relatively uncommon compared to older diabetes medications that push insulin out regardless of what’s happening in the bloodstream.
Why Dual-Action Drugs Produce More Weight Loss
Tirzepatide (sold as Zepbound for weight loss and Mounjaro for diabetes) works differently from semaglutide because it activates two hormone receptors instead of one. In addition to GLP-1, it mimics another gut hormone called GIP (glucose-dependent insulinotropic polypeptide). This dual action appears to explain its edge in clinical trials, where it produced roughly 21% body weight loss at the highest dose compared to about 15% for semaglutide alone.
The way tirzepatide interacts with the GLP-1 receptor is also unusual. Rather than activating the receptor in the same pattern as natural GLP-1, it triggers a biased signaling response that causes less receptor desensitization. In plain terms, the receptor doesn’t “tune out” the drug’s signal as quickly, which may help sustain its effects over time. Meanwhile, GIP receptor activation appears to improve insulin sensitivity through a mechanism that works independently of weight loss, providing metabolic benefits on top of the appetite suppression.
What Happens to Muscle During Weight Loss
One concern with these drugs is that they don’t only burn fat. Studies show that somewhere between 25% and 39% of the total weight lost over 36 to 72 weeks comes from fat-free mass, which includes muscle. That means for every 10 pounds lost, roughly 3 to 4 pounds may be muscle rather than fat.
This ratio is similar to what’s seen with other forms of rapid weight loss, including calorie restriction and bariatric surgery, but the sheer amount of weight these drugs help people lose makes the absolute muscle loss more significant. Losing substantial muscle mass can affect strength, mobility, and metabolic rate, particularly in older adults. Resistance training during treatment is the most practical way to preserve muscle, though research on optimizing body composition during GLP-1 therapy is still catching up with how quickly these drugs have been adopted.
How the Drugs Are Taken
Both semaglutide and tirzepatide are self-administered as weekly injections using a pre-filled pen, similar to an insulin pen. The needle is small and goes just under the skin, typically in the abdomen, thigh, or upper arm. Oral versions of semaglutide also exist, though the injectable form is more commonly used for weight loss.
Dosing follows a gradual escalation schedule designed to minimize side effects. Tirzepatide, for example, starts at 2.5 mg weekly for the first four weeks, then increases to 5 mg. From there, the dose can be bumped up in 2.5 mg increments every four weeks or longer, up to a maximum of 15 mg. Semaglutide follows a similar pattern, starting low and building up over several months. This slow titration gives your gut time to adjust, reducing (though not eliminating) the nausea that comes with these drugs.
Triple-Action Drugs on the Horizon
The next generation of weight loss drugs adds a third hormone to the mix. Retatrutide, currently in late-stage clinical trials, activates receptors for GLP-1, GIP, and glucagon. Glucagon is best known for raising blood sugar, but it also increases energy expenditure and promotes fat breakdown in the liver. Early trial results showed average weight loss of over 70 pounds, suggesting the three-receptor approach may push efficacy even further. If approved, it would represent another step in the rapid evolution of these medications from diabetes treatments to some of the most effective weight loss tools ever developed.